Visual impairment as a function of visual acuity in both eyes and its impact on patient reported preferences

10.1371/journal.pone.0081042PLoS ONE812-POLN

Almost total protection from age-related macular degeneration by haplotypes of the Regulators of Complement Activation

Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. It has been proposed that the polymorphism encoding Y402H (T1277C) in the complement factor H gene (CFH) is one of the main determinants of disease. We genotyped the polymorphism at a number of loci in the region encompassing the Regulators of Complement Activation (RCA) on chromosome 1, including T1277C SNP, in 187 patients and 146 controls. Haplotypes have been classified as protective (P) or susceptible (S) with respect to AMD. This included the identification of an S haplotype with a T at 1277. The results show that no single locus should be assumed to be directly responsible for AMD, but rather argue for the existence of RCA haplotypes, which can be assigned meaningful predictive values for AMD. We conclude that the critical sequences are within a region 450. kb centromeric to 128. kb telomeric of CFH

Effects of simvastatin on retinal structure and function of a high-fat atherogenic mouse model of thickened bruch's membrane

10.1167/iovs.13-11636Investigative Ophthalmology and Visual Science551460-468IOVS

Dietary ω-3 fatty acid and fish intake in the primary prevention of age-related macular degeneration: A systematic review and meta-analysis

10.1001/archopht.126.6.826Archives of Ophthalmology1266826-833AROP

Alcohol Consumption and the Risk of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

10.1016/j.ajo.2007.12.005American Journal of Ophthalmology1454707-715.e2AJOP

Retinal Vascular Caliber and Macular Telangiectasia Type 2

10.1016/j.ophtha.2008.09.009Ophthalmology1162319-323OPHT

Re: Guymer et al.: Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD Randomized Controlled Clinical Trial (Ophthalmology. 2019;126:829-838) Reply

Abstract not availableRobyn H. Guymer, Zhichao Wu, Fred K. Chen, Usha Chakravarthy, Jennifer J. Arnold ... Shane R.Durkin ... et al

Physical Activity and Age-related Macular Degeneration: A Systematic Literature Review and Meta-analysis

Item does not contain fulltextPURPOSE: To better understand the association, in a white population, of physical activity and age-related macular degeneration (AMD)-the main cause of irreversible severe vision loss in developed countries-given the suggestion that a healthy lifestyle may assist in delaying the onset and progression of AMD. DESIGN: Systematic review and meta-analysis. METHODS: Medline, EMBASE, and Google Scholar were systematically searched for studies up to May 2015. Reference lists of published articles were hand searched and study authors were contacted to provide additional data. Those in the lowest category of activity in each study were compared with all other participants to assess the association between physical activity and both early and late AMD using random-effects meta-analysis. RESULTS: Nine studies (subject age range 30-97 years) were included in the meta-analysis. Physical activity was found to have a protective association with both early AMD (8 studies, n = 38 112, odds ratio (OR) 0.92, 95% confidence interval [CI] 0.86-0.98) and late AMD (7 studies, n = 28 854, OR 0.59, 95% CI 0.49-0.72). CONCLUSIONS: Physical activity is associated with lower odds of early and late AMD in white populations. These findings have important implications, reinforcing the public health message of staying active throughout life. However, further longitudinal studies are required to confirm and further characterize a protective effect of physical activity on the onset and/or progression of AMD

Multiallelic copy number variation in the complement component 4A (C4A) gene is associated with late-stage age-related macular degeneration (AMD)

Molecular Technology and Informatics for Personalised Medicine and Healt

Prospective Longitudinal Evaluation of Nascent Geographic Atrophy in Age-Related Macular Degeneration.

PURPOSE:Nascent geographic atrophy (nGA) describes features on OCT imaging previously observed to precede the development of atrophy. This study sought to prospectively evaluate the predictive ability of nGA for the conventional clinical endpoint of geographic atrophy (GA) as defined on color fundus photography (CFP). DESIGN:Prospective, longitudinal, observational study. PARTICIPANTS:A total of 284 eyes from 142 participants with bilateral large drusen and without nGA nor late age-related macular degeneration (AMD) at baseline were included. METHODS:OCT volume scans and CFP images were obtained from all participants at baseline and then at 6-month intervals for up to 36 months. OCT and CFP images were graded independently for the presence of nGA and GA, respectively. Eyes that developed neovascular AMD were censored at the day of its detection. MAIN OUTCOME MEASURES:Time to development of GA. RESULTS:A total 12 eyes from 10 participants progressed to GA over 36 months of follow-up, and nGA was detected in 10 of these eyes (83%) at a preceding visit (median, 13 months prior; interquartile range, 6-25 months). A total of 40 eyes from 28 participants developed nGA or GA over 36 months of follow-up, and the probability of progression to nGA and GA after 36 months was 20% (95% confidence interval [CI], 14%-28%) and 9% (95% CI, 6%-13%), respectively. After the detection of nGA, the probability of progression to GA was 38% (95% CI, 15%-55%) after 24 months. The development of nGA was associated with a markedly increased risk of progression to GA compared with when it did not develop (adjusted hazard ratio, 78.1; 95% CI, 13.6-448.0; P < 0.001), and the development of nGA explained 91% of the variance in the time to GA development. CONCLUSIONS:This study prospectively demonstrated that nGA was a strong predictor for the development of GA, providing supportive evidence of the potential value of nGA as a surrogate endpoint in future intervention trials for the early stages of AMD to improve their feasibility substantially.Zhichao Wu, Chi D. Luu, Lauren A.B. Hodgson, Emily Caruso, Nicole Tindill, Khin Zaw Aung, Myra B. McGuinness, Galina Makeyeva, Fred K. Chen, Usha Chakravarthy, Jennifer J. Arnold, Wilson J. Heriot, Shane R. Durkin, Robyn H. Guyme